Article
Potential clinical implications of BRAF mutations in histiocytic proliferations.
Oncotarget - 30 Jun 2014
Bubolz Anna-Maria, Weissinger Stephanie E, Stenzinger Albrecht, Arndt Annette, Steinestel Konrad, Brüderlein Silke, Cario Holger, Lubatschofski Anneli, Welke Claudia, Anagnostopoulos Ioannis, Barth Thomas F E, Beer Ambros J, Möller Peter, Gottstein Martin, Viardot Andreas, Lennerz Jochen K
Abstract excerpt
For a growing number of tumors the BRAF V600E mutation carries therapeutic relevance. In histiocytic proliferations the distribution of BRAF mutations and their relevance has not been clarified. Here we present a retrospective genotyping study and a prospective observational study of a patient treated with a BRAF inhibitor. Genotyping of 69 histiocytic lesions revealed that 23/48 Langerhans cell lesions were...
Topics
- Adolescent
- Adult
- Aged
- Cell Proliferation
- Child
- Child, Preschool
- Female
- Genotype
- Histiocytes
- Humans
- Infant